Category: Commercial
PharmaSignal — Commercial
The Omnichannel Gap: Building the CRM of the Future for Patient Services
Drug Channels
Today’s guest post comes from Karishma Desai, Associate Director of Data Strategy at Claritas Rx.
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
BioPharma Dive
Some 1,390 Foundayo prescriptions were written in two days, according to analysts.
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
BioSpace
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given
Revolution doubles stock offering target to $2B following pancreatic cancer win
BioSpace
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt o
J&J sets the tone for Q1 earnings with strong oncology growth
Pharmaceutical Technology
Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde
J&J leans on Tremfya, cancer drugs to overcome Stelara losses
BioPharma Dive
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.
With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026
BioSpace
With robust sales performance from oncology darling Darzalex and immunology superstar Tremfya, Johnson & Johnson is “off to a fast start in 2026,” CEO Joaquin Duato told investors on Tuesday.
Alamar, Hemab, Kailera, and Seaport advance IPOs
Pharmaphorum
The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.
With oral obesity race underway, all eyes are on Lilly’s Foundayo launch
BioSpace
Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill.
Senju launches first-in-class dry eye disease drug in Japan
Pharmaphorum
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk
BioPharma Dive
After winning the battle for injectable obesity medicines, Lilly hopes Foundayo can help it catch up in the oral market, where Novo has a three-month lead.
Activist investor renews its criticism of Novavax
Pharmaphorum
Shah Capital has fired another broadside at vaccine firm Novavax, accusing its board and management of a “destruction in shareholder value.”
Approvals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences
BioSpace
After Eli Lilly achieved the milestone approval of the weight loss pill Foundayo, Novo Nordisk launched a full-court press to defend oral Wegovy, which has been enjoying a record-breaking launch since
Novo hits back at rivals with cut-price Wegovy subscriptions
Pharmaphorum
Trying to claw back market share in the weight-loss category, Novo Nordisk has launched a subscription-based service for Wegovy cash payers.
Novartis, Takeda Add Hundreds to Workforce Chopping Block
BioSpace
Follow along as BioSpace tracks job cuts and restructuring initiatives.
The Rare Journey Needs a Special Pharmacy Partner
Drug Channels
Today’s guest post is from Bansi Nagji, Chief Executive Officer at PANTHERx Rare.